BBT-877

Status
Phase 1
Condition
Idiopathic Pulmonary Fibrosis
Intervention Type
Oral Drug
Funder Type
Industry

Drug Details

BBT-877 is a potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis.

Study Purpose

This clinical trial is the first-in-human study of BBT-877. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of BBT-877 in healthy adult subjects.

Find a Clinical Trial

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >